Thu 20 Aug 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission | National Cancer Institution | Ongoing | RITUXIMAB | 3 | EA4151 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer | NRG Oncology King Faisal Specialist Hospital & Research Center | Ongoing | CISPLATIN (CISPLATYL ) | 2 | NRG-HN002 | KFSH & RC-R |
| "A Randomized controlled Trial of Influenza Vaccine to Reduce Adverse Vascular Events" | McMaster University | Ongoing | Vaxigrip | 3 | version 2 | KKUH |
| "A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Stroke and Death in Patients with Acute Ischaemic Stroke or Transient Ischaemic Attack [THALES - Acute STroke or Transient IscHaemic Attack Treated with TicAgreLor and ASA for PrEvention of Stroke and Death] " | AstraZeneca | Completed | Ticagrelor | 3 | D5134C00003 | KFMC |
| A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease (HESTIA3) | Astrazeneca | Ongoing | Ticagrelor | 3 | D5136C00009 | KFMC |
| A prospective, randomized, double-blind, multicenter, placebo-controlled, parallel group, adaptive Phase 3 study with open-label extension to evaluate efficacy and safety of macitentan 75 mg in inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension. | Actelion Pharmaceuticals Ltd | Completed | Macitentan (ACT-064992, Opsumit ®) | 3 | 67896062CTP3001 | King Fahad Medical City (Riyadh) |
| "A Phase IIIb, Single-arm Study to Evaluate the Safety and Immunogenicity of Arabio Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 56 Years and Above in Saudi Arabia" | Arabio | Completed | Meningococcal Conjugate Vaccine (MenACWY-CRM) (Aramen) | 3b | ARA/001/16 | KKUH |
| A phase IIIb, open, multi-country, controlled, randomized study to demonstrate the immunogenicity and safety of GSK Biological meningococcal conjugate vaccine, MenACWYTT (GSK134612) in healthy infants, given on a 3+1 primary and booster (2, 4, 6 and 15-18 months of age), a 1+1 primary and booster (6 and 15-18 months of age), or as a single dose at 15-18 months of age | GSK | Rejected | Infanrix-IPV/HiberixTM/SynflorixTM/GSK 134612 | 3b | 114858 | KFMC |
| A Phase IIIb, Interventional, Multicentre, Multinational, Randomised, Open-label Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 vs. Day 6 in Women Between 36 and 42 Years of Age Undergoing Assisted Reproductive Technique (ART) | Merck Serono | Terminated | Lutropin alfa | 3b | EMR200061_506 | KAUH-J |
| A Phase III, Randomized, doublE-blind, placebo-controlled trial to evaluate Immunogenicity and Safety of the Gam-COVID-Vac combined vector vaccine in prophylactic Treatment for SARS-СoV-2 infection in Saudi Arabia | King Abdullah International Medical Research Center (KAIMRC) | Completed | Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2-induced coronavirus infection. | 3 | RC20/497/R | King Abdulaziz Medical City NG (Riyadh) |
Last update date: 08/05/2025 at 03:17 PM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.